FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016103085> ?p ?o ?g. }

• W2016103085 endingPage "318" @default.
• W2016103085 startingPage "314" @default.
• W2016103085 abstract "HuM195 is a humanized, unconjugated, anti-CD33 monoclonal antibody. Fifty adult patients with relapsed or refractory AML were randomized to receive HuM195 at a dose of 12 or 36 mg/m2 by intravenous infusion over 4 h on days 1–4 and 15–18. Patients with stable or responding disease received two additional cycles on days 29–32 and 43–46. HuM195 was given as first salvage therapy in 24 patients and as second or subsequent salvage therapy in 26 patients. Pretreatment blast percentage in the marrow was between 5 and 30% in 20 patients with the others having blast counts greater than 30%. The median age of patients was 62 years (range 26–86) and CD33 was detected in 95% of patients for whom immunophenotyping was available. Of 49 evaluable patients, two complete and one partial remission were observed. All three responses were in patients treated at the 12 mg/m2 dose level and all had baseline blast percentages less than 30%. Decreases in blast counts ranging from 30 to 74% were seen in nine additional patients. Infusion-related events of fever and chills occurred in the majority of patients and were generally mild and primarily related to the first dose of antibody. No hepatic, renal or cardiac toxicities were observed and other adverse events such as nausea, vomiting, mucositis and diarrhea were uncommon or felt to be unrelated to HuM195. In addition, anti-HuM195 responses were not detected. HuM195 as a single agent has minimal, but observable, anti-leukemic activity in patients with relapsed or refractory AML and activity is confined to patients with low burden disease. No significant differences in clinical efficacy or toxicity were seen between the two dose levels of antibody. HuM195 was well tolerated with infusion-related fevers and chills the predominant toxicities seen. Meaningful clinical efficacy of this unconjugated monoclonal antibody may be realized only in patients with minimal residual disease, or in combination with chemotherapy." @default.
• W2016103085 created "2016-06-24" @default.
• W2016103085 creator A5000999149 @default.
• W2016103085 creator A5001607309 @default.
• W2016103085 creator A5006680533 @default.
• W2016103085 creator A5011922168 @default.
• W2016103085 creator A5034290129 @default.
• W2016103085 creator A5036224917 @default.
• W2016103085 creator A5040539933 @default.
• W2016103085 creator A5055703943 @default.
• W2016103085 creator A5059343191 @default.
• W2016103085 creator A5060144939 @default.
• W2016103085 creator A5060881884 @default.
• W2016103085 creator A5084409602 @default.
• W2016103085 date "2003-02-01" @default.
• W2016103085 modified "2023-10-12" @default.
• W2016103085 title "Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195" @default.
• W2016103085 cites W1562680005 @default.
• W2016103085 cites W1842764967 @default.
• W2016103085 cites W1974926775 @default.
• W2016103085 cites W2025248899 @default.
• W2016103085 cites W2093791243 @default.
• W2016103085 cites W2118574589 @default.
• W2016103085 cites W2123133188 @default.
• W2016103085 cites W2132027522 @default.
• W2016103085 cites W2159533632 @default.
• W2016103085 cites W2269690597 @default.
• W2016103085 cites W2273204150 @default.
• W2016103085 cites W267300006 @default.
• W2016103085 doi "https://doi.org/10.1038/sj.leu.2402803" @default.
• W2016103085 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12592328" @default.
• W2016103085 hasPublicationYear "2003" @default.
• W2016103085 type Work @default.
• W2016103085 sameAs 2016103085 @default.
• W2016103085 citedByCount "80" @default.
• W2016103085 countsByYear W20161030852012 @default.
• W2016103085 countsByYear W20161030852013 @default.
• W2016103085 countsByYear W20161030852014 @default.
• W2016103085 countsByYear W20161030852015 @default.
• W2016103085 countsByYear W20161030852016 @default.
• W2016103085 countsByYear W20161030852017 @default.
• W2016103085 countsByYear W20161030852018 @default.
• W2016103085 countsByYear W20161030852019 @default.
• W2016103085 countsByYear W20161030852020 @default.
• W2016103085 countsByYear W20161030852021 @default.
• W2016103085 countsByYear W20161030852022 @default.
• W2016103085 countsByYear W20161030852023 @default.
• W2016103085 crossrefType "journal-article" @default.
• W2016103085 hasAuthorship W2016103085A5000999149 @default.
• W2016103085 hasAuthorship W2016103085A5001607309 @default.
• W2016103085 hasAuthorship W2016103085A5006680533 @default.
• W2016103085 hasAuthorship W2016103085A5011922168 @default.
• W2016103085 hasAuthorship W2016103085A5034290129 @default.
• W2016103085 hasAuthorship W2016103085A5036224917 @default.
• W2016103085 hasAuthorship W2016103085A5040539933 @default.
• W2016103085 hasAuthorship W2016103085A5055703943 @default.
• W2016103085 hasAuthorship W2016103085A5059343191 @default.
• W2016103085 hasAuthorship W2016103085A5060144939 @default.
• W2016103085 hasAuthorship W2016103085A5060881884 @default.
• W2016103085 hasAuthorship W2016103085A5084409602 @default.
• W2016103085 hasBestOaLocation W20161030851 @default.
• W2016103085 hasConcept C10205521 @default.
• W2016103085 hasConcept C121332964 @default.
• W2016103085 hasConcept C126322002 @default.
• W2016103085 hasConcept C141071460 @default.
• W2016103085 hasConcept C142424586 @default.
• W2016103085 hasConcept C176290653 @default.
• W2016103085 hasConcept C197934379 @default.
• W2016103085 hasConcept C2776694085 @default.
• W2016103085 hasConcept C2778496288 @default.
• W2016103085 hasConcept C2778594517 @default.
• W2016103085 hasConcept C2780580376 @default.
• W2016103085 hasConcept C2780775027 @default.
• W2016103085 hasConcept C2780852908 @default.
• W2016103085 hasConcept C28328180 @default.
• W2016103085 hasConcept C54355233 @default.
• W2016103085 hasConcept C71924100 @default.
• W2016103085 hasConcept C86803240 @default.
• W2016103085 hasConcept C87355193 @default.
• W2016103085 hasConcept C90924648 @default.
• W2016103085 hasConceptScore W2016103085C10205521 @default.
• W2016103085 hasConceptScore W2016103085C121332964 @default.
• W2016103085 hasConceptScore W2016103085C126322002 @default.
• W2016103085 hasConceptScore W2016103085C141071460 @default.
• W2016103085 hasConceptScore W2016103085C142424586 @default.
• W2016103085 hasConceptScore W2016103085C176290653 @default.
• W2016103085 hasConceptScore W2016103085C197934379 @default.
• W2016103085 hasConceptScore W2016103085C2776694085 @default.
• W2016103085 hasConceptScore W2016103085C2778496288 @default.
• W2016103085 hasConceptScore W2016103085C2778594517 @default.
• W2016103085 hasConceptScore W2016103085C2780580376 @default.
• W2016103085 hasConceptScore W2016103085C2780775027 @default.
• W2016103085 hasConceptScore W2016103085C2780852908 @default.
• W2016103085 hasConceptScore W2016103085C28328180 @default.
• W2016103085 hasConceptScore W2016103085C54355233 @default.
• W2016103085 hasConceptScore W2016103085C71924100 @default.
• W2016103085 hasConceptScore W2016103085C86803240 @default.
• W2016103085 hasConceptScore W2016103085C87355193 @default.

• next